PROCEPT BioRobotics (NASDAQ:PRCT) Announces Earnings Results, Misses Estimates By $0.01 EPS

PROCEPT BioRobotics (NASDAQ:PRCT) announced its quarterly earnings results on Tuesday. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.01), FiscalAI reports. PROCEPT BioRobotics had a negative return on equity of 27.70% and a negative net margin of 31.82%.The firm had revenue of $94.50 million during the quarter, compared to the consensus estimate of $92.77 million. During the same quarter in the previous year, the firm earned ($0.35) EPS. The business’s revenue for the quarter was up 19.3% on a year-over-year basis.

Here are the key takeaways from PROCEPT BioRobotics’ conference call:

• Q2 revenue rose 19% year over year to $94.5 million, supported by 65 HYDROS system placements, stronger pricing, and 32% growth in U.S. system revenue. Management maintained its full-year revenue guidance of $390 million to $410 million.
• U.S. procedures increased 21% to more than 13,100 but came in below expectations, primarily because of softness in legacy AquaBeam accounts. Full-year procedure guidance was reduced to 54,000–56,000, with the low end assuming no improvement in AquaBeam utilization.
• HYDROS accounts are generating significantly more procedures per account than legacy AquaBeam sites, while launch-team-supported accounts are showing faster time to first case and stronger early utilization. PROCEPT is accelerating replacements, completing 14 in Q2 and now expecting approximately 40 for the full year.
• Operating expenses increased to $89.8 million, driving a $26.9 million net loss and an $11.3 million adjusted EBITDA loss in Q2. The company raised full-year operating expense guidance to $355 million–$360 million, although it still expects positive adjusted EBITDA in Q4.
• The American Urological Association strengthened its recommendation for Aquablation, and PROCEPT completed enrollment of all 280 patients in the WATER IV randomized prostate cancer trial. The company also received FDA IDE approval for a second randomized trial comparing Aquablation with active surveillance.

PROCEPT BioRobotics Price Performance

NASDAQ:PRCT traded down $0.10 during mid-day trading on Tuesday, reaching $18.28. The company’s stock had a trading volume of 3,692,057 shares, compared to its average volume of 1,568,284. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.73 and a quick ratio of 5.51. The firm’s fifty day moving average price is $21.99 and its two-hundred day moving average price is $24.97. PROCEPT BioRobotics has a 12-month low of $16.67 and a 12-month high of $49.90.

Key Stories Impacting PROCEPT BioRobotics

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: Second-quarter revenue rose 19.3% year over year to $94.5 million, exceeding analysts’ $92.77 million estimate. The results were supported by continued growth in the company’s urology surgical-robotics business. PROCEPT BioRobotics Reports Second Quarter 2026 Financial Results

Institutional Trading of PROCEPT BioRobotics

A number of large investors have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd lifted its position in PROCEPT BioRobotics by 436.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company’s stock valued at $29,000 after purchasing an additional 746 shares during the period. US Bancorp DE grew its position in PROCEPT BioRobotics by 175.7% in the 3rd quarter. US Bancorp DE now owns 1,693 shares of the company’s stock worth $60,000 after purchasing an additional 1,079 shares during the period. Kestra Advisory Services LLC bought a new stake in PROCEPT BioRobotics in the 4th quarter worth approximately $68,000. Lazard Asset Management LLC grew its position in PROCEPT BioRobotics by 90.7% in the 2nd quarter. Lazard Asset Management LLC now owns 1,703 shares of the company’s stock worth $98,000 after purchasing an additional 810 shares during the period. Finally, Osaic Holdings Inc. raised its stake in PROCEPT BioRobotics by 20.3% during the 2nd quarter. Osaic Holdings Inc. now owns 2,001 shares of the company’s stock valued at $115,000 after buying an additional 337 shares during the last quarter. 89.46% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

PRCT has been the subject of several recent analyst reports. Wall Street Zen raised shares of PROCEPT BioRobotics from a “strong sell” rating to a “sell” rating in a report on Saturday, April 25th. Citigroup cut shares of PROCEPT BioRobotics to a “hold” rating in a report on Thursday, July 2nd. Truist Financial reissued a “hold” rating and set a $25.00 price target (down from $30.00) on shares of PROCEPT BioRobotics in a research report on Thursday, July 2nd. Piper Sandler restated an “overweight” rating and issued a $35.00 price objective (up from $28.00) on shares of PROCEPT BioRobotics in a report on Thursday, April 30th. Finally, Evercore began coverage on PROCEPT BioRobotics in a research report on Wednesday, June 24th. They issued an “outperform” rating and a $30.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $33.45.

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.